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ABSTRACT 
Objective: The objective of this study was to develop and evaluate a controlled release implant of ciprofloxacin using Bovine Hydroxyapatite-
Chitosan composite and glutaraldehyde as cross-link agent. 
Methods: Ciprofloxacin implants were prepared using Bovine Hydroxyapatite-Chitosan composite composition 70:30. This composite was further 
developed using three different concentrations of glutaraldehyde (0.5%, 0.75%, and 1,0%). Implants were formed into pellets with 4.0 mm 
diameters and weighed 100.0 mg using compression method. Further, the prepared ciprofloxacin implants were characterized for porosity, density, 
water absorption capacity, swelling ratio, degradation test, compressive strength, compatibility studies (FT-IR), morphology (SEM), X-ray 
diffraction study, assay, and in vitro drug release. 
Results: The addition of glutaraldehyde as cross-link agent in ciprofloxacin implants showed controlled release profile of ciprofloxacin over a time 
period 30 d. This is caused by glutaraldehyde formed compact structure, so the porosity, water absorption capacity, and swelling ratio of the 
implants decreased. Scanning Electron Microscope photomicrograph revealed low porosity of the implants after cross-linking with glutaraldehyde. 
The FTIR study confirmed the formation of covalent imine bonds between Chitosan and glutaraldehyde. However, the addition of glutaraldehyde as 
a cross-link agent caused a decrease in the mechanical strength of the implants. Increased concentration of glutaraldehyde reduced the cristalinity 
of BHA and Chitosan, which were confirmed by XRD studies. In consequence, the mechanical strength of the implants decreases.  
Conclusion: The results obtained from this study indicated that glutaraldehyde has the potential effect to retard ciprofloxacin release from Bovine 
Hydroxyapatite-Chitosan-ciprofloxacin implants for 30 d in the treatment of osteomyelitis. 
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INTRODUCTION 
The research about controlled drug delivery systems has been 
developed to fulfill therapeutic requirements in specific diseases. 
One of the medical fields which required controlled drug delivery 
systems is orthopedics. Complication of bone disease or bone 
disturbance which is due to an injury-induced bone defect [1]. 
Hence, the provision of restorative implants is needed to reconstruct 
damaged bone tissue.  
Reconstruction of bone linked to the risk of infection [2]. This is 
caused by the entry of bacteria into bone tissue [3]. Bacteria attached 
on the surface of bone tissue or implants, and then made a biofilm 
layer. Biofilm layer which is produced by bacteria could protect 
themselves from antibiotics and human immune systems [3. 4]. 
Administration of long period, intravenous antibiotics and oral 
antibiotics had several limitations in bone infection (osteomyelitis) [5]. 
Tissue devascularization in a bone defect caused obstruction of 
antibiotic delivery systems in target tissue. Moreover, giving high 
doses of antibiotics in a long period caused systemic toxicity and side 
effects [5,6]. To overcome this problem, antibiotics could be given 
locally using controlled drug delivery systems. Controlled drug 
delivery systems produced drug release in specific site for a specific 
time period [7]. Therefore, drug delivery systems were developed to 
optimize the therapeutic properties of drug products and render them 
more safe, effective, and reliable. Implantable drug delivery systems 
are an example of such systems available for therapeutic use [8].  
The release of antibiotics in bone tissue was expected to last 
continuously for a definite period with concentration more than MIC 
(Minimum Inhibitory Concentration). One of the antibiotics, which 
had bactericidal properties of the bacteria in the case of bone 
infection (osteomyelitis) is ciprofloxacin. Ciprofloxacin has been 
most widely used fluoroquinolone for bacterial bone infection since 
the minimal inhibitory concentration (MIC) of ciprofloxacin is low 
(0.25-2 μg/ml) for most of the pathogens that cause osteomyelitis 
such as Staphylococcus aureus, Staphylococcus epidermidis, 
Pseudomonas aeruginosa, and Proteus mirabilis [9, 10]. Biomaterial 
implants which act as the ciprofloxacin controlled delivery system 
can be developed as an alternative therapy in osteomyelitis. 
Biomaterial which is used to design implants must be biocompatible, 
biodegradable, osteoconductive, angiogenic, and the mechanical 
strength could support the structure of bone tissue [11].  
The composite can be designed as a biomaterial to get adequate 
physical capability and controlled the release of ciprofloxacin. The 
combination of Bovine Hydroxyapatite as inorganic material and 
chitosan as organic material could construct implants with porous 
structure and adequate mechanical strength to support bone 
formation. Calcified bone contains about 25% organic matrix, 5% 
water, and 70% inorganic mineral (hydroxyapatite) [12]. The 
composite can be designed using similar composition with the bone 
component to obtain good physical characteristics of the implants. 
The composition of Bovine Hydroxyapatite and chitosan in the 
composite can be formed in 70:30 ratio. The previous study revealed 
that drug release from hydroxyapatite-chitosan composite was so 
fast. Approximately 30% of tetracycline hydrochloride was released 
from the scaffolds during the initial 2 hour. An almost complete drug 
release of 93% was reached for the composite within 120 hour [13]. 
However, hydroxyapatite-chitosan composites assessed inadequate 
for the delivery of antibiotics during 4-6 w in osteomyelitis. The 
addition of glutaraldehyde as a cross-linking agent was purposed to 
enhance physical characteristics of the implants and obtained 
controlled release profile of ciprofloxacin. Optimization of 
glutaraldehyde concentration was made in three different 
concentrations. The concentration of glutaraldehyde was 0.5%; 
0.75%; and 1.0%. 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 1, 2016 
Rani et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 45-51 
46 
MATERIALS AND METHODS 
Materials  
Ciprofloxacin was a gift sample from Shangyu Jingxin Pharmaceutical, 
Shangyu, China CO., LTD. Bovine Hydroxyapatite was obtained from 
Tissue Bank of Dr. Soetomo Teaching Hospital, Surabaya, Indonesia. 
Chitosan was obtained from PT. Biotech Indonesia, Cirebon, Indonesia. 
Glutaraldehyde 25%, glacial acetic acid, Na2HPO4, KH2
Chitosan flakes were dissolved in acetic acid solution (1%) v/v. The 
solution was stirred at 400 rpm with a mechanical stirrer for 24 h to 
produce chitosan solution with 2% w/v concentration. 1 M NaOH 
solution was added to chitosan solution (2% w/v) until the pH 
reached neutral (pH =7) to produce chitosan gels. Chitosan gels 
were dried at 40 °C for 24 h. Dried chitosan gels were sieved using 1 
mm sieve to obtain homogeneous chitosan powder.  
PO4, and NaCl 
were products of Merck Millipore, Germany. Aquabidestilata was a gift 
sample from PT. Widatra Bhakti, Pasuruan, Indonesia. All other 
ingredients used were of analytical grade.  
Methods 
Preparation of homogeneous chitosan powder 
Formulation of bovine hydroxyapatite-chitosan-ciprofloxacin 
implants using glutaraldehyde as cross-linking agent  
Ciprofloxacin were dissolved in aqua bidest lata, Bovine 
Hydroxyapatite added gradually and mixed until homogen. Chitosan 
powder was added to ciprofloxacin-Bovine Hydroxyapatite blend. 
Aquabidestilata were added gradually with continuous stirring until 
form wet granules mass. Wet granules mass were sieved using 1 mm 
sieve and dried overnight (24 h) at 40 °C to obtain dried granules. 
Dried granules were immersed in glutaraldehyde solution (0.5%, 
0.75%, and 1.0% concentration) for 24 h until the colour was 
changed [14]. The composition of various formulations was made in 
table 1. Granules were washed three times with aqua bidestilata to 
remove the residual glutaraldehyde. At the final stage, granules were 
washed with phosphate buffer saline (PBS) pH 7.40. Granules were 
dried in an oven 40 °C for 24 h. Dried granules were weighed 100 
mg, pressed using tablet press machine with 4.0 mm diameters and 
the compression pressure was 2 tons.  
 
Table 1: Formulation of implants using glutaraldehyde as cross-link agent 
Formulation code Composite composition (Bovine Hydroxyapatite: chitosan) Glutaraldehyde concentration (%v/v) 
F1 70:30 0.5 
F2 70:30 0.75  
F3 70.30 1.0 
 
Mechanism of crosslinking 
Aldehyde groups of glutaraldehyde (C=OH) react with chitosan 
amino groups (-NH2
 
) produced covalent crosslinking through a 
Schiff base reaction [15].  
 
Fig. 1: Cross-linking reaction of glutaraldehyde (1) and chitosan 
(2) [15] 
 
Evaluation of implants 
Density and porosity test  
The density of the implant was obtained by weighing the implant 
and calculating the volume of the implant. Density was calculated 






Where, Wi is the weight of the implant at initial condition 
V is volume of the implant 
Porosity test was conducted by weighing the implant in the initial 
condition (at time = 0). The implant was placed in 5 ml water for 1 
minute. The implant was taken out from the water at an appropriate 
interval and blotting away the excess water using filter paper. The 




 x 100 
Where, Ww is the wet weight, Wi is initial weight 
Swelling and water uptake study 
Dry implant was weighed and immersed in 5 ml phosphate buffer 
saline (PBS) pH 7.4 at temperature 37 °C±.0.5 °C. The implant was 
withdrawn at appropriate intervals, and then the implant was gently 
blotted with filter paper to remove the excess water and weighed 
again. The percentage of swelling ratio and water uptake of the 
implant was calculated using following equation [16-19].  
Swelling ratio =  
Ww−Wi
Ww
 x 100  
Water absorption capacity =  
Ww−Wi
Wi
 x 100  
Where, Wi is the weight of implant in dry state 
Ww is the weight of the implant after immersion process in 
phosphate buffer saline (PBS) pH 7.40. 
Degradation test  
Degradation test was done by immersing the implant at 5 ml 
phosphate buffer saline pH 7.4 at 37 °C±0.5 °C. Visually inspection 
was done to observe the changing of implant structure which was 
caused by erosion and degradation [20-22].  
Hardness test 
The hardness of the implant was tested by the autograph E-10 
instrument. The implant was pressed by load cell compression 
machine 5 mm/min. The hardness of the implant obtained from the 
force (F in newton unit) which was displayed at the instrument 
divided by contact surface area of the implant (in mm unit) [20]. 
Evaluation of implant morphology using scanning electron 
microscope (SEM)  
The morphology of the implant was examined in scanning electron 
microscope (SEM). The samples were fitted to aluminum stubs with 
conductive paint and were sputter-coated with gold. Pore diameter 
was calculated from SEM micrograph. The pore size was calculated 
using a minimum 40 pores from different places of the cross-section 
of the implant [23].  
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Drug content  
One milled implant was placed in 100 ml HCL 0.1 N and stirred for 
24 h (400 rpm) until form suspension. The suspension was 
sonicated for 30 min. After sonication process, the filtrate of the 
suspension was filtered using millipore membrane with 0.45 mm 
diameter. The filtrate was pipetted 1 ml, transferred in a 25 ml 
volumetric flasks, and diluted using phosphate buffer saline (PBS) 
pH 7.4. The absorbance of this solution was observed using 
spectrophotometer UV-Vis at three wavelengths (260 nm, 270 nm, 
and 280 nm). ∆ Absorbance which was obtained from the 
observation extrapolated in standard curve equation to obtain 
ciprofloxacin HCL concentration [24]. 
In vitro drug release study  
Drug release from the implant was studied by vial method. The drug 
release study was performed by immersing the implant in a vial 
containing 5 ml of phosphate buffer saline (PBS) pH 7.4. Vial was 
placed in a shelf and incubated in water bath at 37 °C±0.5 °C. 
Sampling was conducted by pipetting 1 ml of elution fluids at 
predetermined time intervals (1st, 3rd, 5th, 7th, 9th, 12th, 14th, 16th, 18th, 
20th, 22th, and 24th
Data analysis  
 h on first day and every 24 h for 30 d) and 
replaced with fresh buffer to maintain sink condition. The sample 
solution was filtered with millipore membrane (ø = 0.45 um 
(micrometer)). Appropriate dilution was prepared using phosphate 
buffer saline (PBS) pH 7.4. The absorbance of the solution was 
analyzed using UV spectrophotometer at three wavelengths (260 
nm, 270 nm, and 280 nm). Drug concentration in the sample was 
determined using standard calibration curve. Cumulative percent 
drug release was found at each time interval. The release of 
ciprofloxacin HCL from the implants was assayed in triplicate, mean 
and S. D was also determined [22, 25].  
The results of implant evaluation (density, porosity, swelling ratio, 
water uptake, hardness, and AUC of in vitro release profile) were 
statistically analyzed using one-way Analysis of Variance (ANOVA) 
with 95% confidences interval.  
Characterization of implants  
Fourier transforms infrared (FTIR) spectroscopy  
Fourier transform of infrared (FTIR) spectroscopy was conducted in 
the wave number range 4000-400 cm-1
X-ray diffraction study  
. The sample was combined 
with KBr and pressed into a pellet. The solid pellet was analyzed 
using FT-IR spectroscopy [23].  
The X-ray diffraction study was carried out to determine the crystal 
phases of the implant using monochromatic Cu Kα radiation (40 KV, 
30 MA). The 2θ scan range was 5-50 °. X-ray diffraction peaks of the 
implants were compared to the diffraction peaks of pure materials 
(ciprofloxacin HCL, Bovine Hydroxyapatite, and chitosan) [23].  
RESULTS AND DISCUSSION  
Formulation of bovine hydroxyapatite-chitosan-ciprofloxacin 
implants using glutaraldehyde as cross-link agent  
Formulation of the implants was begun by producing dry granules. 
Dry granules were brown, spherical in shape, and the diameters 
were approximately 1 mm. Dry granules then pressed using tablet 
machine to produce cylindrical pellet with 4 mm diameters.  
Evaluation of implants 
Density and porosity 
The density of the implant with three different concentration of 
glutaraldehyde can be seen in fig. 3. Statistically analysis using one-
way anova showed that there was no significant difference of 
density between the implants which used three different 
concentration of glutaraldehyde (P>0.05). Based on this results, 
could be concluded that the difference of glutaraldehyde 
concentration did not affect the implant density. 
 
Fig. 2: Formulation process of bovine hydroxyapatite-chitosan-
ciprofloxacin implants using glutaraldehyde, A) dry granules, 
B) implants (cylindrical pellets) 
 
 
Fig. 3: Density of F1 to F3 formulations 
 
The porosity of the implant with three different concentrations of 
glutaraldehyde is shown in Fig.4. Porosity of F3 (1.0% 
glutaraldehyde) was significantly different with F1 (0.5% 
glutaraldehyde) (*P<0.05). Increasing glutaraldehyde concentration 
of 1% caused a decrease in porosity than 0.5% glutaraldehyde. The 
increase of glutaraldehyde concentration caused the structure of the 
implants became more compact. Glutaraldehyde affected network 
size which was formed between chitosan chains. The increase of 
glutaraldehyde concentration led to the size of the network became 
smaller, so that the pores diameter also decreased [26].  
Swelling and water uptake study  
The swelling ratio of F1 to F3 formulation is indicated in fig. 5. The 
swelling mechanism depends on protonation of amino groups in 
chitosan molecules. Protonation caused repulsion of chitosan chains 
and dissociation of interactions like intramolecular hydrogen 
bonding [26, 27]. Cross-linking process with glutaraldehyde could 
decrease protonation of amino groups in chitosan molecules, reduce 
the relaxation of chitosan chain, and lower repulsion mechanism of 
chitosan chains. Based on this condition, F1 to F3 showed low 
swelling ratio of the implants. 
 
 
Fig. 4: Porosity of F1 to F3 formulations 
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Fig. 5: Swelling ratio of F1 to F3 formulations 
 
Water uptake of formula 1 (0.5% glutaraldehyde) was significantly 
different from formula 3 (1.0% glutaraldehyde) (**P<0.01). The 
increase of glutaraldehyde concentration to 1.0% caused markedly 
decrease in implant water uptake capacity. Cross-linking process 
with glutaraldehyde restricted water molecules to enter into 
chitosan structure [27]. Therefore, the highest concentration of 
glutaraldehyde (1.0%) produced an implant with the lowest water 
uptake capacity. Percent water uptake of F1 to F3 formulation can 
be seen in fig. 6. 
 
 
Fig. 6: Water uptake of F1 to F3 formulations 
 
Degradation test  
The degradation profile of implants with three different 
concentrations of glutaraldehyde showed that formula with the 
lowest degradation was F2 (glutaraldehyde 0.75%). At the opposite, 
F1 (glutaraldehyde 0.5%) showed greater degradation than two 
others formula. The lower concentration of glutaraldehyde as a 
cross-link agent caused hydrolysis process in polymer chains 
inducting erosion process [28]. Because of this phenomenon, F1 
easier to degrade compare to two others formula. The increase of 
glutaraldehyde concentration caused an increase in cross-link 
density. Implants with higher cross-link density had lower 
hydrophilic groups, so that the structure of the implants became 
difficult to extend in water [29]. Limitation of expansion ability was 
caused by the compact structure of the implants after cross-link 
process. But, increasing glutaraldehyde concentration of 1.0% in F3 
produced implants with higher degradation ability compares to F2 
(glutaraldehyde 0.75%). In general, degradation of the implants 
decrease as the cross-linking degree increased because of the more 
dense covalently linked network. For the specific case, a more 
complex relationship is found between cross-linking degree with 
glutaraldehyde and degradation rate, because the crystalline content 
in the material is also changing [29]. This condition was 
demonstrated by F3 which easier to degrade compare to F2. The 
crystalinity of F3 was lower than F2, so that the ability of water to 
penetrate in implants structure became easier and the implants 
degrade easily [30].  
Hardness 
Hardness of the implants (F1 to F3) is as shown in fig. 7. The increase of 
glutaraldehyde concentration to 1.0 % in F3 caused a significant 
decrease of implants hardness compare to F1 and F2. Using high 
concentration of glutaraldehyde as cross link agent caused modification 
of implants structure became amorph [30]. Cross-linking process using 
glutaraldehyde caused the characteristic of biomaterial became brittle. 
Increasing glutaraldehyde as cross-link agent more than 0.2 % decreases 
the mechanical strength of the implants [31].  
 
 
Fig. 7: Hardness of F1 to F3 formulations 
 
Evaluation of implants morphology using scanning electron 
microscope (SEM) 
SEM micrograph of the implant is presented in fig. 8. Surface 
morphology of the implant after the cross-linking process was 
dense, rough, and porous. The structure of the implant was porous 
and composed of irregular pores. In this structure, chitosan covered 
Bovine Hydroxyapatite particles which seemed as hexagonal 
particles. This condition led to the structure of the implant became 
compact, the pores became smaller, and the number of pores 
decreases [29]. F3 showed the smallest pore size among three 
formulas and the number of pores became lower. Increasing 
glutaraldehyde concentration caused a decrease of pore size. 
Drug content 
All the implants had a uniform distribution of ciprofloxacin HCL in 
all the formulations. Drug content of all formulations was 
determined by UV spectrophotometer using three-wavelength 
methods and reported in table 2. 
Table 2: Drug content of F1 to F3 formulations 





In vitro drug release study 
The cumulative percent release from three formulations (F1 to F3) 
was determined and shown fig. 9. The release profile of ciprofloxacin 
HCL from the implants showed that ciprofloxacin release was at a 
therapeutic level of ciprofloxacin for osteomyelitis (2-50 μg/ml) [32-
33]. This condition could be kept for 30 d. Take into account this 
profile, it could be concluded that glutaraldehyde inhibited the burst 
release of ciprofloxacin from the implants. Area under curve (AUC) 
of F1 to F3 was calculated and analyzed being used one way ANOVA 
to compare the release of ciprofloxacin from three formulas. In 
general, an increase of glutaraldehyde concentration decreased the 
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drug release from the implants [28]. But, increasing glutaraldehyde 
concentration to 1.0 % in F3 showed no significant difference of 
ciprofloxacin release compared to F2. The decrease of material 
crystallinity after cross-linking process caused implants structure 
became amorph, so that ciprofloxacin was easier to dissolve and 
release from the implants [30]. 
 
   
Fig. 8: SEM micrograph of the implants, A): F1 (0.5% glutaraldehyde), B): F2 (0.75% glutaraldehyde), C): F3 (1.0% glutaraldehyde)
 
Fig. 9: Ciprofloxacin release profile of F1 to F3 formulations 
 
Characterization of implants 
Fourier transformed infrared spectroscopy (FT-IR)  
The infrared spectrum of ciprofloxacin, Bovine Hydroxyapatite, 
chitosan, implants Bovine Hydroxyapatite-chitosan-ciprofloxacin 
before the cross-linking process, and implants Bovine 
Hydroxyapatite-chitosan-ciprofloxacin after the cross-linking 
process with three different concentrations of glutaraldehyde (F1 to 
F3) is shown in fig. 10. In the spectrum of the implants before cross-
linking with glutaraldehyde, chitosan absorption bands situated at 
1658.67 cm-1 (C=O stretching in amide group). Some changes can be 
noted after the cross-linking process with glutaraldehyde. The peak 
at 1658.67 cm-1 shifts to lower wave numbers ~ 1630 cm-1. This 
band is most probably composed of amide I band of chitosan 
(appears at 1658.67 cm-1) and the C=N stretching band of Schiff’s 
base that according to the literature appears at wave number 1620-
1660 cm-1[15]. Moreover, it is not observed any band at ~1715 cm-1, 
connected with free aldehyde group. The increase of glutaraldehyde 
concentration to 1.0% caused a successive increase in the intensity 
of the ethylene bond (C=C) at 1583 cm-1 [27]. This fact can be 
attributed to the increase of glutaraldehyde molecule contribution in 
the cross-linking reaction so that this condition increases the 
crosslinking chain [27]. Infrared spectrum of the implants after 
cross-linking process also showed a shift of N-H and O-H stretching 
vibration of chitosan molecules (3475.49 cm-1) to 3420 cm-1
X-ray diffraction study 
 in 
implants. This condition indicated interactions between the 
materials which composed the implants.  
X-ray diffraction of the implants after cross-linking process are shown in 
fig. 11. X-ray diffractogram of the implants are compared with X-ray 
diffraction of Bovine Hydroxyapatite, chitosan, ciprofloxacin, and the 
implants before the cross-linking process. The X-ray pattern of chitosan 
shows major crystalline peaks at 2θ ≈ 10 ° and 2θ ≈ 20 °. But, the X-ray 
diffraction of the implants indicated that these peaks became wider and 
weaker. The decrease crystallinity of chitosan molecules caused by the 
deformation of hydrogen bond in the molecular structure of chitosan. 
Substitution of glutaraldehyde molecules destroyed the regular 
structure of chitosan molecules so that the structure of chitosan 
molecules became amorph [34]. 
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Fig. 10: FTIR spectrum of, (A): Bovine hydroxyapatite; (B): 
Chitosan; (C) Ciprofloxacin; (D) Glutaraldehyde; (E) Implants 
before cross-linking process; (F): Formula 1; (G): Formula 2; (H): 
Formula 3 
 
Moreover, the characteristic peaks intensity of Bovine Hydroxyapatite in 
2θ ≈ 26 ° and 2θ ≈ 32 ° decreased in X-ray diffraction of the implants 
after cross-linking process compared to X-ray diffraction of pure BHA 
and the implants before the cross-linking process. Based on this fact, it 
could be concluded that increasing glutaraldehyde concentration caused 
the decrease of implants crystallinity [14]. Characteristic peaks of 
ciprofloxacin also did not observe in X-ray diffraction of the implants 
after the cross-linking process. This condition indicated that 
ciprofloxacin was molecularly dispersed in the structure of the implants.  
 
Fig. 11: X-ray diffraction spectrum of (A): Chitosan; (B): Implant 
before cross-linking process; (C) Formula 1; (D) Formula 2; (E) 
Formula 3; (F): Bovine Hydroxyapatite; (G): Ciprofloxacin 
 
CONCLUSION 
Bovine Hydroxyapatite-chitosan-ciprofloxacin implants with 
glutaraldehyde as cross-link agents are characterized by low 
porosity, low water uptake capacity, and minimal swelling ratio. But, 
glutaraldehyde decreased the mechanical strength of the implants 
due to the decrease of material crystallinity. The addition of 
glutaraldehyde as cross-link agent in Bovine Hydroxyapatite-
chitosan-ciprofloxacin implants produced controlled release profile 
of ciprofloxacin. Glutaraldehyde inhibited burst release of 
ciprofloxacin from the implants. The release of ciprofloxacin from 
the implants ranged from in vitro therapeutic level of ciprofloxacin 
for osteomyelitis. Therefore from this study it is proved that Bovine 
Hydroxyapatite-chitosan-ciprofloxacin implants with glutaraldehyde 
as a cross-link agent has a potential to control ciprofloxacin release 
for thirty days in the treatment of osteomyelitis.  
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